热门资讯> 正文
Neoleukin Therapeutics报告财年业绩
2025-03-25 04:24
- Neoleukin Therapeutics press release (NASDAQ:NGNE): FY Revenue of $0.93M beats by $0.16M.
- Net income for the twelve months ended December 31, 2023 included a one-time $16.4 million bargain purchase gain related to the reverse merger.
- Cash, cash equivalents and marketable securities as of December 31, 2024, were $312.4 million and are expected to provide runway into the second half of 2027, which would allow for the completion of enrollment of a future registrational trial for NGN-401 for Rett syndrome, CMC scale-up to support NGN-401 registrational activities and further development of Neurogene’s EXACT™ gene therapy pipeline.
More on Neoleukin Therapeutics
- Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401
- Seeking Alpha’s Quant Rating on Neoleukin Therapeutics
- Historical earnings data for Neoleukin Therapeutics
- Financial information for Neoleukin Therapeutics
推荐文章
特朗普即将揭晓“AI行动计划”，这些美股有望赢政策利好，谁将从中“分羹”？
美股异动丨英伟达、博通跌超3%，稳定币巨头Circle跌超7%
美股机会日报丨鲍威尔发言在即！散户疯炒，“Meme股”OPEN盘前涨超23%
华盛早报丨要求审查美联储！美财长贝森特激进发言；"Meme股"黑马Opendoor再暴涨42%触发熔断
特朗普媒体公司囤积20亿美元比特币！加密货币推动特朗普净资产大幅增长
AI和机器人有望刺激特斯拉股价？财报季提前部署期权策略
华盛早报丨科技“七巨头“财报来袭定调美股走向！金融科技公司Block获入标普500指数
美股“七巨头”迎特朗普关税后首次大考！Q2能否交出亮眼成绩单，继续引领美股上涨？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
